Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Income from Continuing Operations (2016 - 2025)

Outlook Therapeutics has reported Income from Continuing Operations over the past 8 years, most recently at 13483952.0 for Q4 2025.

  • Quarterly Income from Continuing Operations rose 37.59% to 13483952.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 94841058.0 through Dec 2025, down 142.54% year-over-year, with the annual reading at 63979492.0 for FY2025, 15.11% up from the prior year.
  • Income from Continuing Operations was 13483952.0 for Q4 2025 at Outlook Therapeutics, up from 14847398.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 13483952.0 in Q4 2025 and troughed at 46357206.0 in Q1 2025.